DOI: 10.36347/sjmcr.2015.v03i08.019

Pages: 711-713

We report our experienced treating diabetic macular edema (DME) patients with intravitreal ranibizumab that not responding to laser photocoagulation. A retrospective case series of DME patients that not responding to focal / grid laser photocoagulation, treated with intravitreal ranibizumabat Hospital University Sains Malaysia from 2011 to 2012. Best corrected visual acuity (BCVA), intraocular pressure (IOP) and central macular thickness (CMT) measurement were performed pre and post intravitreal ranibizumab. Six patients (7 eyes) were included in this case series. All eyes received one injection of intravitreal ranibizumab (0.3mg). Mean logarithm of the minimum angle of resolution (Log MAR) BCVA was 1.2 pre intravitreal ranibizumab and improved to 0.88 at 6 months post injection. Mean CMT was 520 µm pre intravitreal ranibizumab and reduced to 425 µm at 6 months post injection. None of the eye showed any significant raised in IOP post injection. In this small numbers of DME cases, we observed that intravitreal ranibizumab results in improvement of the visual acuity and reduction in CMT in DME patients that not responding to focal / grid laser photocoagulation.